Related Pages for AUROPHARMA
- Option Chain
- Straddle OC
- Max Pain
- Put Call Ratio
- Option Analytics
- Call OI vs Put OI
- Strike Flow
- Call OI Chg vs Put OI Chg
- Call Vol vs Put Vol
- Buildup & Unwinding
- Vega Divergence
- Multi Strike OI
- Multi Straddle Analysis
- Price vs OI
- Time Series Table
- Time Series Multi Chart
- Volatility Skew
- Premium Decay
- IV - HV
- IV Intraday
- Future Chain
- Future Intraday Analysis
- Technical
- Financials
- Chart
- About
No results found.
AUROPHARMA
Related News - AUROPHARMA
Aurobindo Pharma: HSBC on Aurobindo Pharma Maintains Buy with Target Price of ₹1,900 as 1QFY27 delivered healthy growth across Europe, RoW and API despite slower US growth, with respiratory launches from Lannett and new plants such as Pen G and China providing growth drivers; FY27 guidance remains double-digit revenue growth with 21%+ margins.
07 Aug 2026 08:55 AM
Aurobindo Pharma: HSBC on Aurobindo Pharma Maintains Buy with Target Price of ₹1,900 as 1QFY27 delivered healthy growth across Europe, RoW and API despite slower US growth, with respiratory launches from Lannett and new plants such as Pen G and China providing growth drivers; FY27 guidance remains double-digit revenue growth with 21%+ margins.
Aurobindo Pharma: BoFA Securities on Aurobindo Pharma Maintains Buy with Target Price of ₹1,800 as 1QFY27 EBITDA margin stood at 21%, with Lannett growth and margin improvement plus profitable contributions from China/Pen G facilities expected to complement base-business momentum and improve long-term growth visibility.
07 Aug 2026 08:56 AM
Aurobindo Pharma: BoFA Securities on Aurobindo Pharma Maintains Buy with Target Price of ₹1,800 as 1QFY27 EBITDA margin stood at 21%, with Lannett growth and margin improvement plus profitable contributions from China/Pen G facilities expected to complement base-business momentum and improve long-term growth visibility.
Aurobindo Pharma: GS on Aurobindo Pharma Maintains Buy with Target Price of ₹1,750 as 1Q revenue/EBITDA grew 16.3%/20% YoY, driven by strong Europe, growth markets and resilient US growth, while EBITDA margin expanded to 21%; FY27 guidance remains double-digit revenue growth with EBITDA margin above 21%.
07 Aug 2026 08:56 AM
Aurobindo Pharma: GS on Aurobindo Pharma Maintains Buy with Target Price of ₹1,750 as 1Q revenue/EBITDA grew 16.3%/20% YoY, driven by strong Europe, growth markets and resilient US growth, while EBITDA margin expanded to 21%; FY27 guidance remains double-digit revenue growth with EBITDA margin above 21%.
Aurobindo Pharma: Bernstein on Aurobindo Pharma Maintains Market Perform with Target Price of ₹1,498 as Q1 delivered steady top-line and earnings growth across geographies, but US ex-Lannett declined 3%, new product approvals slowed, regulatory inspections may limit incremental growth, and Lannett/Advair upside appears largely priced in.
07 Aug 2026 08:56 AM
Aurobindo Pharma: Bernstein on Aurobindo Pharma Maintains Market Perform with Target Price of ₹1,498 as Q1 delivered steady top-line and earnings growth across geographies, but US ex-Lannett declined 3%, new product approvals slowed, regulatory inspections may limit incremental growth, and Lannett/Advair upside appears largely priced in.
Aurobindo Pharma: CLSA on Aurobindo Pharma Maintains Hold with Target Price of ₹1,600 as 1QFY27 was broadly in line with healthy growth across geographies, while FY27 guidance of double-digit revenue growth and 21% margins was reiterated; new product launches and portfolio expansion are expected to drive the full benefit from FY28.
07 Aug 2026 08:56 AM
Aurobindo Pharma: CLSA on Aurobindo Pharma Maintains Hold with Target Price of ₹1,600 as 1QFY27 was broadly in line with healthy growth across geographies, while FY27 guidance of double-digit revenue growth and 21% margins was reiterated; new product launches and portfolio expansion are expected to drive the full benefit from FY28.
Aurobindo Pharma: Citi on Aurobindo Pharma Maintains Sell with Target Price of ₹1,260 as 1QFY27 slightly beat estimates mainly on lower R&D and favourable currency, while underlying constant-currency growth remained weak at ~4-5%; US growth challenges, 20x FY28E EPS valuation and limited further currency upside remain concerns.
07 Aug 2026 08:56 AM
Aurobindo Pharma: Citi on Aurobindo Pharma Maintains Sell with Target Price of ₹1,260 as 1QFY27 slightly beat estimates mainly on lower R&D and favourable currency, while underlying constant-currency growth remained weak at ~4-5%; US growth challenges, 20x FY28E EPS valuation and limited further currency upside remain concerns.
Aurobindo Pharma: Expects Eugia's FY27 Revenue To Reach $500 Million.
06 Aug 2026 10:37 AM
Aurobindo Pharma: Expects Eugia's FY27 Revenue To Reach $500 Million.
Aurobindo Pharma: Plans To Merge Eugia Steriles And Eugia SEZ With Eugia Pharma Specialities.
05 Aug 2026 07:55 PM
Aurobindo Pharma: Plans To Merge Eugia Steriles And Eugia SEZ With Eugia Pharma Specialities.
AUROBINDO PHARMA: Q1 CONS NET PROFIT 10.33B RUPEES VS 8.2B (YOY)
05 Aug 2026 07:51 PM
AUROBINDO PHARMA: Q1 CONS NET PROFIT 10.33B RUPEES VS 8.2B (YOY)
AUROBINDO PHARMA: Q1 REVENUE 91.5B RUPEES VS 77.9B (YOY)
05 Aug 2026 07:51 PM
AUROBINDO PHARMA: Q1 REVENUE 91.5B RUPEES VS 77.9B (YOY)
AUROBINDO PHARMA: Q1 EBITDA 21B RUPEES VS 16B (YOY) || Q1 EBITDA MARGIN 23.07% VS 20.37% (YOY)
05 Aug 2026 07:51 PM
AUROBINDO PHARMA: Q1 EBITDA 21B RUPEES VS 16B (YOY) || Q1 EBITDA MARGIN 23.07% VS 20.37% (YOY)
Aurobindo Pharma: Company Enters Agreement with MSD for Generic Alimta Prevention Medicine.
25 Jul 2026 10:19 AM
Aurobindo Pharma: Company Enters Agreement with MSD for Generic Alimta Prevention Medicine.
Aurobindo Pharma: Enters Non-Exclusive License Agreement With MSD.
24 Jul 2026 09:50 PM
Aurobindo Pharma: Enters Non-Exclusive License Agreement With MSD.
Aurobindo Pharma: Citi on Aurobindo Pharma Maintains Sell with Target Price raised to ₹1,270 (from ₹1,020) as the recent rally has pushed valuations to 2 SD above historical averages, already pricing in FX and PLI benefits, while FY28–29 growth is expected to slow due to limited pipeline visibility, weaker Lannett prospects, modest long-term PAT CAGR, and stretched valuations at 20x FY28E EPS.
10 Jul 2026 08:56 AM
Aurobindo Pharma: Citi on Aurobindo Pharma Maintains Sell with Target Price raised to ₹1,270 (from ₹1,020) as the recent rally has pushed valuations to 2 SD above historical averages, already pricing in FX and PLI benefits, while FY28–29 growth is expected to slow due to limited pipeline visibility, weaker Lannett prospects, modest long-term PAT CAGR, and stretched valuations at 20x FY28E EPS.
Aurobindo Pharma: Transfers Domestic Branded Generic Pharma Business To Wholly Owned Subsidiary Auropharm Limited Effective July 1, 2026.
02 Jul 2026 10:38 AM
Aurobindo Pharma: Transfers Domestic Branded Generic Pharma Business To Wholly Owned Subsidiary Auropharm Limited Effective July 1, 2026.
Aurobindo Pharma: Co Completes Acquisition Of Lannet By Aurobindo Pharma USA INC., A Unit Of Co.
30 Jun 2026 09:56 AM
Aurobindo Pharma: Co Completes Acquisition Of Lannet By Aurobindo Pharma USA INC., A Unit Of Co.
Aurobindo Pharma: US FDA Inspection Ends With Two Noted Issues, Response Due Within Required Timeframe.
27 Jun 2026 03:07 PM
Aurobindo Pharma: US FDA Inspection Ends With Two Noted Issues, Response Due Within Required Timeframe.
HSBC on Aurobindo Pharma – Buy | TP: ₹1,580 | Lannett acquisition to drive US business closer to USD 2 billion sales by FY27; gAdvair launch seen as a key catalyst.
22 Jun 2026 09:11 AM
HSBC on Aurobindo Pharma – Buy | TP: ₹1,580 | Lannett acquisition to drive US business closer to USD 2 billion sales by FY27; gAdvair launch seen as a key catalyst.
Aurobindo Pharma: Aurobindo Pharma USA Gets FTC Green Light For $250 Million Lanett Buy
22 Jun 2026 08:13 AM
Aurobindo Pharma: Aurobindo Pharma USA Gets FTC Green Light For $250 Million Lanett Buy
Aurobindo Pharma: Gets FTC Green Light For Lannett Buy, Deal Expected To Close This Month.
19 Jun 2026 08:44 AM
Aurobindo Pharma: Gets FTC Green Light For Lannett Buy, Deal Expected To Close This Month.
